Dublin, Jan. 30, 2026 (GLOBE NEWSWIRE) — The “Breast Cancer Liquid Biopsy Testing Devices Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031” has been added to ResearchAndMarkets.com’s offering.
The Global Breast Cancer Liquid Biopsy Testing Devices Market is projected to expand significantly, rising from USD 895.36 Million in 2025 to USD 2.34 billion by 2031, reflecting a CAGR of 17.41%.
These devices, which include diagnostic platforms and assay kits, are engineered to isolate and analyze circulating tumor cells or circulating tumor DNA from blood samples for oncological evaluation.
This growth trajectory is chiefly propelled by the rising incidence of breast carcinomas combined with the clinical necessity for frequent, non-invasive monitoring to detect treatment resistance. Additionally, the industry is buoyed by the transition toward precision medicine, which demands detailed genomic profiling without the inherent risks of repeated tissue biopsies. Highlighting the urgency for scalable diagnostic solutions, the American Cancer Society estimates that approximately 316,950 women in the United States will be diagnosed with invasive breast cancer in 2025.
One significant challenge hampering the widespread expansion of this market is the lack of standardized reimbursement policies and the high cost associated with next-generation sequencing assays. Inconsistent coverage across different healthcare systems creates financial barriers that limit patient access to these molecular diagnostic tools. Furthermore, the variability in assay sensitivity and the requirement for substantial clinical validation data to secure regulatory approval continue to delay market entry for new entrants, thereby impeding rapid commercial adoption.
Market Drivers
The Rising Global Incidence and Prevalence of Breast Cancer constitutes the foundational driver propelling the demand for scalable liquid biopsy solutions. As the burden of disease intensifies worldwide, healthcare systems are increasingly prioritizing non-invasive tools that can provide frequent genomic profiling without the logistical and clinical complications of tissue extraction. This escalating patient population necessitates high-throughput screening and monitoring capabilities that only molecular diagnostics can efficiently sustain on a global scale.
Simultaneously, Advancements in Next-Generation Sequencing (NGS) and Digital PCR Technologies are removing technical barriers to entry and accelerating commercial adoption. These technological innovations have significantly enhanced the sensitivity of assays, allowing for the precise detection of low-frequency circulating tumor DNA mutations that were previously undetectable, thereby validating the clinical utility of liquid biopsies for treatment selection and recurrence monitoring. This technical maturation is directly reflected in the surging volume of clinical testing.
Market Challenges
The lack of standardized reimbursement policies and the high costs associated with next-generation sequencing assays present a formidable barrier to the expansion of the Global Breast Cancer Liquid Biopsy Testing Devices Market. Insurers frequently classify these advanced molecular tests as investigational rather than medically necessary, resulting in fragmented coverage and unpredictable payment models across different healthcare regions. This financial ambiguity discourages clinicians from prescribing liquid biopsies, as they cannot ensure that patients will be insulated from significant expenses. Consequently, clinical laboratories face difficulties in justifying the capital investment required for these diagnostic platforms, effectively slowing the operational momentum needed for market expansion.
These economic hurdles directly restrict patient access to precision medicine, narrowing the addressable market for device manufacturers. When third-party payers deny claims or impose high deductibles, patients often decline testing despite its potential to guide therapy or monitor recurrence.
Market Trends
The Rising Adoption of Minimal Residual Disease (MRD) Monitoring is transforming clinical protocols by enabling the detection of microscopic tumor fragments long before radiological recurrence. This trend addresses the critical gap in post-surgical surveillance, where traditional imaging often fails to identify occult metastases until they are clinically advanced. By utilizing tumor-informed assays, clinicians can now stratify patients based on their real-time recurrence risk, allowing for timely therapeutic intervention.
Concurrently, the Integration of Artificial Intelligence for Enhanced Biomarker Discovery is reshaping the competitive landscape by decoding complex genomic datasets to identify novel therapeutic targets. Market players are increasingly leveraging machine learning algorithms to analyze vast amounts of clinical and molecular data, thereby improving the sensitivity of liquid biopsy panels and operationalizing precision oncology at scale. This technological convergence is driving substantial commercial growth as providers adopt these AI-enhanced platforms for more accurate profiling.
Key Players Profiled in the Breast Cancer Liquid Biopsy Testing Devices Market
- A Menarini AG
- NeoGenomics Laboratories Inc.
- F Hoffmann-La Roche AG
- Myriad Genetics Inc.
- QIAGEN NV
- Biocept Inc.
- Sysmex Corp
- Fluxion Biosciences Inc.
- Thermo Fisher Scientific Inc.
- Epic Sciences Inc.
Report Scope
In this report, the Global Breast Cancer Liquid Biopsy Testing Devices Market has been segmented into the following categories:
Breast Cancer Liquid Biopsy Testing Devices Market, by Offerings:
- Assay & Reagents Kits
- Instruments
Breast Cancer Liquid Biopsy Testing Devices Market, by Circulating Biomarker:
- Circulating Tumor DNA
- Circulating Tumor Cell
- Extracellular Vesicles
Breast Cancer Liquid Biopsy Testing Devices Market, by Application:
- Cancer Applications
- Non-Cancer Applications
Breast Cancer Liquid Biopsy Testing Devices Market, by Region:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 183 |
| Forecast Period | 2025 – 2031 |
| Estimated Market Value (USD) in 2025 | $895.36 Million |
| Forecasted Market Value (USD) by 2031 | $2340 Million |
| Compound Annual Growth Rate | 17.4% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/eremix
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Breast Cancer Liquid Biopsy Testing Devices Market
